Streetbeat News

Products Services

ABBV

AbbVie announced positive results from its Phase 3 TEMPO-1 trial for Tavapadon as a monotherapy in early Parkinson's disease, showing significant improvement in MDS-UPDRS scores. Results from the TEMPO-2 flexible-dose trial are expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:02 pm

BKSY

BlackSky Technology Inc. has secured a U.S. Navy research contract to develop advanced optical intersatellite links for its Gen-3 satellites. This project supports the Navy's Project Overmatch and the Department of Defense's JADC2 initiatives, providing real-time imagery to military operations.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:02 pm

SVMH

SRIVARU Holding Limited (NASDAQ:SVMH) has received CMVR certification for its PRANA 2.0 electric motorcycles in India, marking a significant step in entering the expanding Indian EV market. This certification is crucial for revenue generation and aligns with SRIVARU's continued Nasdaq listing.

Portfolio Pulse from Vandana Singh

September 26, 2024 | 12:00 pm

NVO

VANI

Vivani Medical (NASDAQ:VANI) has received approval for a clinical trial in Australia for its obesity treatment implant. The trial will assess the safety and efficacy of the exenatide NanoPortal implant, with data expected in 2025. Vivani aims to use the trial data for regulatory submissions globally.

Portfolio Pulse from Vandana Singh

September 26, 2024 | 12:00 pm

SVMH

SRIVARU has secured approval from India's Road Transport Authority for its PRANA 2.0 vehicle, marking a step towards achieving final federal technical compliance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:00 pm

VANI

Vivani Medical announced that their upcoming study will be the first clinical application of their NanoPortal drug implant platform technology. This marks a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:00 pm

VANI

Vivani Medical has received regulatory approval to start its first human clinical trial for a GLP-1 implant targeting obesity and overweight conditions in Australia.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:00 pm

KTTA

MU

TBIO

Micron Technology reported better-than-expected Q4 results, boosting its stock by 17%. Telesis Bio's partnership with Beckman Coulter Life Sciences led to a 148% surge in its stock. Pasithea Therapeutics announced positive data from its Phase 1 trial, increasing its stock by 69%.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:59 am

BAX

Baxter has introduced its new Vest Advanced Pulmonary Experience System at the North American Cystic Fibrosis Conference. This system is designed to aid in daily therapy for individuals with chronic lung conditions, offering improved comfort and features based on user feedback.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:58 am

DOGEUSD

SHIBUSD

Dogecoin and Shiba Inu, two leading meme coins, are experiencing significant price surges. Shiba Inu's burn rate has increased dramatically, and the introduction of the SHI stablecoin is expected to enhance its ecosystem. Meanwhile, Dogecoin has seen substantial whale activity, suggesting a potential bullish breakout.

Portfolio Pulse from Khyathi Dalal

September 26, 2024 | 11:54 am